- Visitors will discover how The Roche Integrated Core Lab (ICL) provides labs and clinicians with a vast array of diagnostic testing within one single automated system, expanding efficiency, connectivity and the quality of their diagnostic capabilities
- The new cobas t 711 coagulation analyzer will be unveiled, together with the next generation of the cobas® analytical clinical chemistry and immunochemistry platform
- The newly launched cobas m 511 integrated hematology analyzer will also be exhibited
- Delegates will have the opportunity to discuss lab consultancy and services at Roche’s state-of-the-art booth, as well as attend four educational workshops and a variety of presentations on women’s health, Alzheimer’s disease and cardiac diagnostics
- Roche will be donating €10 for each photo taken at the booth in support of Cœur pour Tous (Hearts for All), a charity that offers vital access to heart surgery for children in need
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will be showcasing new solutions for lab innovation and leadership at the 22nd IFCC–EFLM European Congress of Clinical Chemistry and Laboratory Medicines (EuroMedLab) in Athens, Greece, 11–15 June.
The congress will offer the opportunity to experience first-hand Roche’s latest technological advancements in diagnostics technology and solutions, including the Roche Integrated Core Lab (ICL).
At Roche we strive to deliver high-quality solutions and services across healthcare settings for the benefit of providers and patients, said Jean-Claude Gottraux, Head of Centralised and Point of Care Solutions. Our technologies continue to inform swift and clinically-validated decision making, enabling patients to receive the right intervention at the right time across the globe.
Automation and connectivity for unprecedented efficiency
Roche will be showcasing its Integrated Core Lab, a new approach and response to an increasingly complex and challenging healthcare environment. The enterprise-wide connectivity and best-in-class technology help laboratories to compete in a demanding market —generating unprecedented efficiency, extending quality and improving control for a greater impact on patient care.
For the first time, the next generation of the cobas analytical clinical chemistry and immunochemistry platform, can be viewed, along with the newly launched cobas m 511 and cobas t 711 integrated hematology and coagulation analyzers.
The cobas t 711 will be launched at the end of 2017 offering innovative features, including improved processing power and increased walkaway time for the mid- to high-volume coagulation laboratories. It will be connected to the cobas connection modules (CCM). Some of its main features include connectivity, automated reagent reconstitution, and optimized reagent and sample management, which will provide laboratories with improved workflow and operating efficiency.
The cobas m 511 enables patients to benefit from faster results for the accurate diagnosis of blood diseases, as diverse as anemia and leukemia1. Significantly, the cobas m 511 requires only small sample volumes, so the blood requirements from vulnerable groups such as the elderly, intensive care patients and neonates are greatly reduced.
Attendees can also learn how Roche is leading the way with full automation and integration of Molecular Diagnostics providing laboratories with improved operating efficiency and the flexibility to adapt to the changing demands of diagnostic testing. For example, the cobas 6800 and cobas 8800 systems offer the fastest turnaround times for high-throughput laboratories and the longest walk-away times among automated molecular platforms.2 In addition the cobas CT/NG for use on the cobas® 6800/8800 System provides laboratories with the highest throughput solution for the testing of CT/NG on the market.
Providing fast answers to patients’ most pressing questions
We offer sophisticated testing solutions that allow doctors to make the very best decision for the patient, said Jean-Jacques Palombo, Senior Vice President at Roche. Our newly launched fertility companion diagnostic, Elecsys® AMH Plus, delivers results which aid more efficient and more targeted clinical decisions, linked to a woman’s personal biology. That means less anxiety for the woman, and better medical decisions made by the doctor.
Roche will share the importance of diagnostics in:
- Women’s health with the first companion diagnostic to be approved in fertility (AMH plus) and the pre-eclampsia ratio (sFlt-1/PlGF)
- Alzheimer’s disease and the need for improved diagnostic tools
- Cardiac assays including NT-proBNP and the novel marker GDF-15,and how these tests can improve decision making in cardiovascular disease and thereby improve patients’ lives
Highlights of Roche Diagnostics at EuroMedLab
During the entirety of the exhibition, Roche will be sharing its booth with Cœur pour Tous (Hearts for All) a charity offering vital access to heart surgery, particularly to children in need. Attendees are invited to show support by having their photo taken and posting it onto the booth’s digital wall. For every photograph taken Roche will donate €10 to the charity.
Digital Diagnostics – decision support from lab to bedside
Monday 12 June 14:30–15:30 EduW5
Dr. Ralph Schimmer, CMO and Global Head of Medical & Scientific Affairs, Centralised and Point of Care Solutions, Roche Diagnostics, Rotkreuz, will chair a session including a look at current digital healthcare innovations and the challenges of digitized health information in the 21st century.
Laboratory’s role in enhancing clinical decision making for cardiac and pregnancy carest
Monday 12 June 15:45-16:45 EduW9
Prof. Gerasimos Filippatos, Athens University Hospital Attikon, Greece and Prof. Damien Gruson, Brussels, Belgium, will co-chair a dynamic session looking at natriuretic peptides in the era of ARNI drugs, the novel biomarker GDF-15 and the ABC bleeding risk score for patients with atrial fibrillation, as well as advancements in diagnosing and predicting pre-eclampsia through angiogenic markers.
Using cell-free DNA as basis for clinical applications
Tuesday 13 June 14:30–15:30 EduW21
Prof Konstantinos Syrigos, Medicine & Medical Oncology, Athens School of Medicine, Greece, will lead a session covering cell-free DNA testing for fetal aneuploidy and NGS-based testing of liquid biopsy samples in lung cancer.
New approaches in diagnosis and management of sexually transmitted diseases and emerging infections
Tuesday 13 June 15:45-16:45 EduW22
Prof Marco Cusini, Fondazione IRCCS, Ca' Granda Ospedale Maggiore Policlinico Milan, Italy, will chair a session around HIV 4th-generation screening tests, syphilis diagnosis and the Zika virus.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.